Impact Biomedical (IBO) Cash from Operations (2022 - 2026)
Impact Biomedical's (IBO) quarterly Cash from Operations came in at 464000.0 in Q1 2026, up 31.96% YoY from 351608.89 in Q1 2025, and down 568.69% on a QoQ basis from 99000.0 in Q4 2025.
Impact Biomedical (IBO) Cash from Operations (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Cash from Operations data on file, last reported at 464000.0 in Q1 2026.
- Quarterly Cash from Operations rose 31.96% year-over-year to 464000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1672000.0 (up 45.25% YoY) and the FY2025 annual result came in at 1890000.0, up 33.78% from the prior year.
- Cash from Operations fell to 464000.0 in Q1 2026, from 99000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 99000.0 in Q4 2025 to a low of 1014000.0 in Q1 2023.
- A 5-year average of 614933.33 and a median of 671000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 127.71% — and 2025, when it soared 110.04%.
- Tracing IBO's Cash from Operations over 5 years: stood at 363000.0 in 2022, then declined by 19.28% to 433000.0 in 2023, then sank by 127.71% to 986000.0 in 2024, then soared by 110.04% to 99000.0 in 2025, then tumbled by 568.69% to 464000.0 in 2026.
- The last three Cash from Operations figures came in at 464000.0 (Q1 2026), 99000.0 (Q4 2025), and 613000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 470,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 470,000.00 |
| Jun 30, 2026 | 470,000.00 |
| Mar 31, 2026 | -464,000.00 |
| Mar 31, 2026 | -464,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Sep 30, 2025 | -613,000.00 |
| Sep 30, 2025 | -613,000.00 |
| Jun 30, 2025 | -694,000.00 |
| Jun 30, 2025 | -694,000.00 |
| Mar 31, 2025 | -682,000.00 |
| Mar 31, 2025 | -682,000.00 |
| Dec 31, 2024 | -986,000.00 |
| Dec 31, 2024 | -986,000.00 |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -385,000.00 |
| Jun 30, 2024 | -385,000.00 |
| Mar 31, 2024 | -482,000.00 |
| Mar 31, 2024 | -482,000.00 |